Association between first-trimester maternal serum pregnancy-associated plasma protein-A and obstetric complications

2013 ◽  
Vol 33 (9) ◽  
pp. 839-847 ◽  
Author(s):  
Francesco D'Antonio ◽  
Claudia Rijo ◽  
Basky Thilaganathan ◽  
Ranjit Akolekar ◽  
Asma Khalil ◽  
...  
Keyword(s):  
Plasma Protein ◽  
Protein A ◽  
First Trimester ◽  
Maternal Serum ◽  
Obstetric Complications

scholarly journals First Trimester Biochemical Screening for Trisomy 21: The Role of Free Beta hCG, Alpha Fetoprotein and Pregnancy Associated Plasma Protein A

1994 ◽  
Vol 31 (5) ◽  
pp. 447-454 ◽  
Author(s):  
K Spencer ◽  
D A Aitken ◽  
J A Crossley ◽  
G McCaw ◽  
E Berry ◽  
...  
Keyword(s):  
Chorionic Gonadotropin ◽  
Plasma Protein ◽  
Human Chorionic Gonadotropin ◽  
Trisomy 21 ◽  
False Positive Rate ◽  
Protein A ◽  
First Trimester ◽  
Serum Markers ◽  
Maternal Serum ◽  
Detection Rates

The potential efficacy of screening for trisomy 21 in the first trimester, using maternal serum markers α fetoprotein, free β human chorionic gonadotropin, unconjugated oestriol and pregnancy associated plasma protein A, was studied in an unselected population of women between the seventh and fourteenth week of gestation. Using a combination of α fetoprotein and free β human chorionic gonadotropin, 53% of affected pregnancies could be identified at a false positive rate of 5%. Unconjugated oestriol and pregnancy associated plasma protein A levels were lower in cases of trisomy 21, but their inclusion with other markers did not significantly improve detection rate. Monitoring the same pregnancies also in the second trimester showed that screening in the first trimester identified the same cases as in the second. We conclude that first trimester screening using free β human chorionic gonadotropin and α fetoprotein, is a viable possibility and will lead to detection rates in excess of 50%. Prospective studies are needed to confirm these observations.

scholarly journals Double-monoclonal immunofluorometric assays for pregnancy-associated plasma protein A/proeosinophil major basic protein (PAPP-A/proMBP) complex in first-trimester maternal serum screening for Down syndrome

1997 ◽  
Vol 43 (12) ◽  
pp. 2323-2332 ◽  
Author(s):  
Qiu-Ping Qin ◽  
Michael Christiansen ◽  
Claus Oxvig ◽  
Kim Pettersson ◽  
Lars Sottrup-Jensen ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Plasma Protein ◽  
Basic Protein ◽  
Protein A ◽  
First Trimester ◽  
Maternal Serum ◽  
Major Basic Protein ◽  
Maternal Serum Screening ◽  
Detection Rates ◽  
Serum Screening

Abstract Four double-monoclonal time-resolved immunofluorometric assays (TrIFMAs) have been developed for the specific determination of pregnancy-associated plasma protein A/proeosinophil major basic protein (PAPP-A/proMBP) complex in first-trimester maternal serum samples. The assays have a functional sensitivity of <4 mIU/L and a working range from 4 to 1000 mIU/L. These 4 assays, together with a polyclonal sandwich TrIFMA, were compared for their ability to discriminate between normal pregnancies (n = 149) and pregnancies carrying a Down syndrome fetus (n = 36) in maternal serum screening samples from gestational weeks 4–13. In 26 Down syndrome pregnancies from gestational weeks 7–12, the median PAPP-A multiples of the median concentration in controls (MoMs) determined by monoclonal antibody combinations 234–3/234–2*, 234–4/234–2*, 234–4/234–5*, and 234–5/234–6* were 0.35, 0.37, 0.42, and 0.44, respectively, whereas the median MoM determined by the polyclonal assay was 0.56. ROC curve analysis also showed that better overall diagnostic accuracy and detection rates were achieved by the monoclonal TrIFMAs than by the polyclonal TrIFMA. This report is the first to describe assays that specifically measure PAPP-A/proMBP complex without possible interference from other proMBP-containing complexes.

Pregnancy-associated plasma protein A (PAPP-A): measurement by highly sensitive and specific enzyme immunoassay, importance of first-trimester serum determinations, and stability studies

1995 ◽  
Vol 7 (6) ◽  
pp. 1419 ◽  
Author(s):  
NA Bersinger ◽  
P Marguerat ◽  
G Pescia ◽  
H Schneider
Keyword(s):  
Enzyme Immunoassay ◽  
Plasma Protein ◽  
Protein A ◽  
First Trimester ◽  
Maternal Serum ◽  
Potential Candidate ◽  
Second Trimester ◽  
Freezing And Thawing ◽  
Control Serum ◽  
Repeated Freezing

It has recently been established that maternal serum pregnancy-associated plasma protein A (PAPP-A) was reduced in pregnancies with fetal Down syndrome in the first but not in the second trimester of gestation. In comparison with two other placental proteins, human chorionic gonadotrophin and pregnancy-specific beta 1-glycoprotein, an explanation for this can be formulated based on the large molecular weight of PAPP-A. With the increasing clinical demand for fetal abnormalities to be diagnosed in the first rather than in the second trimester of pregnancy, maternal serum PAPP-A is a strong potential candidate for being used in routine trisomy screening. We have developed a sensitive enzyme immunoassay (ELISA) intended at smaller laboratories due to its long shelf life. Here we show that repeated freezing and thawing, or the addition of iodoacetate (5 mM) did not affect the results, at both high or low concentration of PAPP-A. It is also possible to introduce the serum into the test as a dry sample on blotting paper, easily posted in an envelope. A decrease of 21% was observed after such dry storage for three weeks at room temperature, which can be compensated for by the inclusion of a dried control serum, mailed with the sample(s).

scholarly journals The Relationship Between First-Trimester Aneuploidy Markers and Birth Weight

2021 ◽  
pp. 1-6
Author(s):  
Cenk Soysal ◽  
İsmail Biyik ◽  
Özlem Erten ◽  
Onur Ince ◽  
Hatice Sari ◽  
...  
Keyword(s):  
Plasma Protein ◽  
Gestational Age ◽  
Small For Gestational Age ◽  
Protein A ◽  
First Trimester ◽  
Nuchal Translucency ◽  
Maternal Serum ◽  
Large For Gestational Age ◽  
Aneuploidy Screening ◽  
Beta Human Chorionic Gonadotropin

OBJECTIVE: We aimed to determine the relationship between the first-trimester aneuploidy screeningma and the predicted weight at birth: Small for gestational age and large for gestational age. STUDY DESIGN: 594 low-risk pregnant women with a singleton pregnancy, who underwent first-trimester aneuploidy screening by measuring nuchal translucency, maternal serum free beta-human chorionic gonadotropin, and pregnancy-associated plasma protein-A were included in the study. Those weighing above the 3rd percentile and below the 10th percentile were defined as small for gestational age, and those over the 90th percentile were defined as large for gestational age. RESULTS: A total of 594 pregnant women were enrolled. The mean maternal age of the studied group was 28.8±5.5 years. Low maternal serum pregnancy-associated plasma protein-A levels and decreased nuchal translucency measurements were associated with the small for gestational age newborn (p<0.001 and p=0.001, respectively). There is a significant correlation with large for gestational age for newborns only with an increase in maternal serum pregnancy-associated plasma protein-A levels (p=0.001). beta-human chorionic gonadotropin levels were not associated with the birth weight (p=0.735). CONCLUSION: Maternal serum pregnancy-associated plasma protein-A levels, one of the markers in first-trimester aneuploidy screening, can be used in the prediction of small for gestational age and large for gestational age However, due to its low correlation, it is not a suitable screening test for clinical practice.

Sign in / Sign up

Export Citation Format

Share Document